Amarillo Biosciences, Inc. (OTCMKTS:AMAR) Files An 8-K Unregistered Sales of Equity Securities

Amarillo Biosciences, Inc. (OTCMKTS:AMAR) Files An 8-K Unregistered Sales of Equity Securities
Item 3.02.

Story continues below

Unregistered Sales of Equity Securities.

On December 12, 2017, the Company placed 7,121,157 shares of its unregistered voting common stock. The aggregate offering price of these shares was $1,335,217 ($.1875 per share), the consideration was cash, and no underwriting discounts were paid or given. On December 14, 2017, the Company placed 2,324,132 shares of its unregistered voting common stock. The aggrigate offering price of these shares was $581,033 ($.25 per share), the consideration was cash, and no underwriting discounts were paid or given. The sale and issuance of the voting common stock are exempt from registration under the Securities Act of 1933 (the "Act") to Rule 506 (b) of Regulation D promulgated under the Act. The conditions of Rules 501, 502, and 506 were met with respect to both offerings, the Form D for the $.1875 offering has previously been filed with the SEC, and the Form D for the $.25 offering will be timely filed with the SEC.


About Amarillo Biosciences, Inc. (OTCMKTS:AMAR)

Amarillo Biosciences, Inc. is engaged in the business of biopharmaceutical research and development. The Company develops biologics for the treatment of human and animal diseases. The Company’s focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form. The Company owns or licenses approximately two issued patents related to the low-dose oral delivery of interferon and it owns an issued patent on its dietary supplement, Maxisal. It has a pending patent, which applies low dose oral interferon to the treatment of Thrombocytopenia.

An ad to help with our costs